Abstract
Human Immunodeficiency virus (HIV) associated neurocognitive disorders have been reported in up to 50% of patients on highly active antiretroviral therapy (HAART) [1]. Even though screening for neurocognitive impairment (NCI) is not routinely done or recommended by current treatment guidelines [2], NCI is associated with HAARTnoncompliance and functional impairment [3], and is currently being linked to cerebrospinal fluid escape (positive CSF HIV RNA PCR in the setting of undetectable serum HIV RNA PCR) [4]. The Montreal cognitive assessment (MoCA) has been validated and widely used in several countries and languages in non-HIV infected populations to screen for cognitive impairment [5,6]. There is very limited data in HIV positive patients [7], a population that is associated with high rates of co-existing infections and comorbidities including depression and drug abuse. The purpose of our study was to evaluate the utility of the MoCA as a screening tool for NCI in HIV infected individuals.
Highlights
Human Immunodeficiency virus (HIV) associated neurocognitive disorders have been reported in up to 50% of patients on highly active antiretroviral therapy (HAART) [1]
After screening a total of 118 patients, 11 patients were excluded because they refused participation in the study and 7 patients because they had prior HAART
Active drug use was seen in 37% of patients and 41% of the patients had moderate to severe depression
Summary
Human Immunodeficiency virus (HIV) associated neurocognitive disorders have been reported in up to 50% of patients on highly active antiretroviral therapy (HAART) [1]. The Montreal cognitive assessment (MoCA) has been validated and widely used in several countries and languages in non-HIV infected populations to screen for cognitive impairment [5,6]. There is very limited data in HIV positive patients [7], a population that is associated with high rates of co-existing infections and comorbidities including depression and drug abuse. The purpose of our study was to evaluate the utility of the MoCA as a screening tool for NCI in HIV infected individuals
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
